Overview

Migraine Induction Properties of PACAP-38 After Eptinezumab in Migraine Without Aura Patients.

Status:
Recruiting

Trial end date:
2023-07-30

Target enrollment:

Participant gender:

Summary

To investigate whether administration of calcitonin gene-related peptide (CGRP) binding monoclonal antibodies eptinezumab prevents pituitary adenylate cyclase-activating polypeptide-38 (PACAP-38) induced migraine attacks in migraine without aura patients.

Phase:

N/A

Details

Lead Sponsor:

Danish Headache Center

Treatments:

Pituitary Adenylate Cyclase-Activating Polypeptide